Clinical characteristics and treatment outcomes of children with anaplastic large cell lymphoma: a single center experience.
- Author:
Jee Yeon HAN
1
;
Jin Kyung SUH
;
Seong Wook LEE
;
Kyung Nam KOH
;
Ho Joon IM
;
Jong Jin SEO
Author Information
- Publication Type:Original Article
- Keywords: Anaplastic large cell lymphoma; Childhood; Prognosis; Relpase
- MeSH: Bone Marrow; Child*; Cohort Studies; Diagnosis; Disease-Free Survival; Drug Therapy; Humans; Lung; Lymph Nodes; Lymphoma, Large-Cell, Anaplastic*; Lymphoma, Non-Hodgkin; Prognosis; Recurrence; Stem Cell Transplantation; T-Lymphocytes
- From:Blood Research 2014;49(4):246-252
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: Anaplastic large cell lymphoma (ALCL) is uncommon in children, accounting for approximately 15% of all cases of childhood non-Hodgkin lymphoma. Despite many studies attempting new treatment strategies, treatment outcomes have not significantly improved, and the optimal treatment for pediatric ALCL has not been established. METHODS: The records of newly diagnosed ALCL patients at our institute between July 1998 and April 2013 were reviewed. We evaluated the general characteristics of the patients, chemotherapy regimens, overall survival (OS) rates, and event-free survival (EFS) rates. RESULTS: Twenty-eight ALCL patients were eligible. The median age at diagnosis was 10.8 years. Lymph node involvement was the most common presentation (79%). CCG-5941, a multi-agent T-cell lineage chemotherapy, was the predominant treatment regimen (57%). The five-year OS and EFS rates were 88% and 69%, respectively. Stage, the presence of B symptoms, lung involvement, and bone marrow involvement were significant prognostic factors for EFS (P=0.02, 0.01, 0.01, and 0.02, respectively). Eight patients relapsed, and three died during the study period. Four of the eight patients who relapsed were treated with high-dose chemotherapy and autologous stem cell transplantation (HDCT-ASCT). Two of the four who had undergone HDCT-ASCT developed secondary relapses and were subsequently treated with allogeneic SCT or brentuximab. CONCLUSION: We found that treatment outcomes with multi-agent chemotherapy in children with ALCL were similar to those of previous reports, and that relapsed patients could be salvaged with HDCT-ASCT or allogeneic SCT. A prospective, larger cohort study is warranted to define the optimal treatment for pediatric ALCL.
